Rtw Investments, LP Relmada Therapeutics, Inc. Transaction History

Rtw Investments, LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$2.24 - $4.76 $143,384 - $304,692	64,011 Added 3.1%	2,131,835 $4.82 Million
Q4 2022 Feb 14, 2023	SELL	$2.17 - $35.84 $1.25 Million - $20.7 Million	-576,651 Reduced 21.81%	2,067,824 $7.22 Million
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $126,160 - $255,215	6,894 Added 0.26%	2,644,475 $97.9 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $1.61 Million - $2.96 Million	97,507 Added 3.84%	2,637,581 $50.1 Million
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $5.91 Million - $9.55 Million	353,750 Added 16.18%	2,540,074 $68.6 Million
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $11 Million - $17.4 Million	648,298 Added 42.15%	2,186,324 $49.3 Million
Q2 2021 Aug 13, 2021	BUY	$29.55 - $39.15 $215,980 - $286,147	7,309 Added 0.48%	1,538,026 $49.2 Million
Q1 2021 May 14, 2021	BUY	$31.52 - $39.28 $568,746 - $708,768	18,044 Added 1.19%	1,530,717 $53.9 Million
Q4 2020 Feb 16, 2021	BUY	$29.88 - $39.8 $39,919 - $53,172	1,336 Added 0.09%	1,512,673 $48.5 Million
Q3 2020 Nov 16, 2020	BUY	$34.42 - $43.78 $1.05 Million - $1.33 Million	30,485 Added 2.06%	1,511,337 $56.9 Million
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $15.7 Million - $24.8 Million	496,310 Added 50.41%	1,480,852 $66.3 Million
Q1 2020 May 15, 2020	BUY	$23.78 - $50.12 $7.61 Million - $16 Million	320,058 Added 48.17%	984,542 $33.6 Million
Q4 2019 Feb 14, 2020	BUY	$10.1 - $47.18 $6.71 Million - $31.4 Million	664,484 New	664,484 $25.9 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $11.7M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Rtw Investments, LP with notifications on news.